- Home
- WOK vs IMRN Comparison
WOK vs IMRN Comparison
Compare WOK & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WOK
- IMRN
- Stock Information
- Founded
- WOK 2002
- IMRN 1994
- Country
- WOK China
- IMRN Australia
- Employees
- WOK N/A
- IMRN N/A
- Industry
- WOK
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- WOK
- IMRN Health Care
- Exchange
- WOK NYSE
- IMRN Nasdaq
- Market Cap
- WOK 9.3M
- IMRN 10.1M
- IPO Year
- WOK 2024
- IMRN N/A
- Fundamental
- Price
- WOK $0.54
- IMRN $1.75
- Analyst Decision
- WOK
- IMRN Strong Buy
- Analyst Count
- WOK 0
- IMRN 1
- Target Price
- WOK N/A
- IMRN $5.00
- AVG Volume (30 Days)
- WOK 227.5K
- IMRN 13.6K
- Earning Date
- WOK 02-03-2025
- IMRN 04-08-2025
- Dividend Yield
- WOK N/A
- IMRN N/A
- EPS Growth
- WOK N/A
- IMRN N/A
- EPS
- WOK N/A
- IMRN N/A
- Revenue
- WOK $11,506,440.00
- IMRN $4,048,286.00
- Revenue This Year
- WOK N/A
- IMRN N/A
- Revenue Next Year
- WOK N/A
- IMRN N/A
- P/E Ratio
- WOK N/A
- IMRN N/A
- Revenue Growth
- WOK N/A
- IMRN 82.90
- 52 Week Low
- WOK $0.50
- IMRN $1.70
- 52 Week High
- WOK $8.45
- IMRN $3.09
- Technical
- Relative Strength Index (RSI)
- WOK N/A
- IMRN 41.07
- Support Level
- WOK N/A
- IMRN $1.73
- Resistance Level
- WOK N/A
- IMRN $2.10
- Average True Range (ATR)
- WOK 0.00
- IMRN 0.12
- MACD
- WOK 0.00
- IMRN 0.01
- Stochastic Oscillator
- WOK 0.00
- IMRN 10.26
About WOK WORK MEDICAL TECHNOLOGY GROUP LTD
WORK Medical Technology Group Ltd is engaged in manufacturing and selling medical consumables through its wholly owned subsidiaries in the People's Republic of China. The Company's main products include medical face masks, tourniquets, airways, breathing circuits, intubation accessories, anesthesia kits, oxygen masks, suction sets, laryngoscope blades, KN95 masks, and other disposable medical devices, as well as medical equipment.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.